PRISM (Panitumumab Regimen In Second-line Monotherapy of head and neck cancer)

- Histologically or cytologically confirmed squamous cell carcinoma of head and neck (SCCHN) of oropharynx, oral cavity, hypopharynx, or larynx with at least 1 measurable lesion using computed tomography (CT) or magnetic resonance imaging (MRI) scan - Diagnosis of recurrent disease determined to be incurable by surgery or radiotherapy - Karnofsky Performance Status (KPS) score ≥ 60% at screening - Men or women age ≥18 years - Adequate hematologic, electrolyte and hepatic functions and negative pregnancy test

- Subject received > 1 chemotherapy regimen for the treatment of metastatic or recurrent disease - Concomitant chemotherapy for recurrent disease administered solely for the purpose of radiation sensitization during re-irradiation will not be counted towards this chemotherapy regimen - Nasopharyngeal carcinoma, salivary gland and primary skin SCCHN, or symptomatic central nervous system (CNS) metastases - History of interstitial lung disease, significant cardiovascular disease, or another primary cancer - Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic hepatitis B infection - Known allergy or hypersensitivity to any component of panitumumab - Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, panitumumab, cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib) for recurrent or metastatic disease with the following exceptions: -- Prior EGFr inhibitor therapy is allowed if received as part of prior multimodality treatment (eg, as radiation sensitizer) and completed > 24 weeks prior to randomization -- Subjects who received no more than one dose of cetuximab and discontinued prior to progression due to documented severe infusion reaction are eligible. - Significant thromboembolic event ≤ 8 weeks prior to enrollment - Subjects not recovered from all previous acute radiotherapy-related toxicities - History of severe skin disorder that in the opinion of the investigator may interfere with study conduct - History of any medical, or psychiatric condition, or laboratory abnormality that may interfere with the interpretation of study results - Subject is currently in a clinical trial ≤ 30 days prior to enrollment - Subjects requiring use of immunosuppressive agents however corticosteroids are allowed - Man or woman of child-bearing potential who do not consent to use adequate contraceptive precautions during the course of the study - Female subject who is pregnant or breast-feeding - Subject requiring major surgery using general/spinal anesthesia ≤ 28 days prior to enrollment, or minor surgery ≤ 14 days prior to enrollment.